BI 764198 for Focal Segmental Glomerulosclerosis
Trial Summary
Will I have to stop taking my current medications?
The trial requires that if you are taking corticosteroids, ACE inhibitors, ARBs, finerenone, aldosterone inhibitors, or SGLT2 inhibitors, you must be on a stable dose for at least 4 weeks before the trial and continue without changing the dose during the trial. You cannot use calcineurin inhibitors or certain cytotoxic agents during the trial.
What is the purpose of this trial?
This trial tests if the medicine BI 764198 can improve kidney health in adults with a specific kidney disease called FSGS. Participants take the medicine regularly for a few months. Their kidney health is checked through urine samples and regular health check-ups.
Eligibility Criteria
Adults with primary focal segmental glomerulosclerosis (FSGS), a type of kidney disease, can join this study. Participants will be tested for their kidney health and must commit to multiple study visits or have a research nurse visit them at home.Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive BI 764198 or placebo as capsules once a day for about 3 months
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- BI 764198
- Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
Boehringer Ingelheim
Lead Sponsor